Skip to main content

Table 1 JAK1 and JAK3-selective inhibitors currently in clinical studies

From: JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

Name Selectivity Patient group Clinical phase
Baricitinib (LY3009104) JAK1/2 Rheumatoid arthritis Phase 3
Psoriasis
Ruxolitinib (INCB18424) JAK1/2 Acute leukemia Phase 1/2
Chronic myeloid leukemia (CML)
Acute myeloid leukemia (AML) FDA approved
Myelofibrosis
Decernotinib (VX-509) JAK3 Rheumatoid arthritis Phase 2/3
Tofacitinib (CP-690550) JAK3 Rheumatoid arthritis FDA approved
INCB039110 JAK1 Primary myelofibrosis Phase 2
Post-polycythemia vera fibrosis
Post-essential thrombocythemia myelofibrosis
PF-04965842 JAK1 Plaque psoriasis Phase 2
Filgotinib (GLPG0634) JAK1 Rheumatoid arthritis Phase 2
Crohn’s disease
INCB047986 JAK1 Rheumatoid arthritis Phase 2
Momelotinib (CYT387) JAK1/JAK2 Primary myelofibrosis Phase 1/2
Post-polycythemia vera myelofibrosis Phase 2
Post-essential thrombocythemia myelofibrosis
Polycythemia vera
Essential thrombocythemia Phase 2
GSK2586184 JAK1 Psoriasis Phase 2
Systemic lupus erythematosus
AT9283 JAK2/JAK3 Multiple myeloma Phase 2
Acute myeloid leukemia Phase 1/2
Acute lymphoblastic leukemia
Chronic myeloid leukemia
Myelodysplastic syndromes
Myelofibrosis